Jul 30, 2026 07:25AM
May 19, 2026 07:25AM
May 19, 2026 07:25AM
May 11, 2026 07:25AM
Apr 30, 2026 07:25AM
Apr 27, 2026 07:25AM
Apr 27, 2026 07:25AM Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
Apr 22, 2026 07:25AM
Apr 22, 2026 07:25AM
Apr 15, 2026 07:25AM
Jan 30, 2026 07:25AM
May 7, 2025 08:16AM
Mar 26, 2024 10:25AM
Mar 26, 2024 10:25AM Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
Aug 15, 2023 07:25AM
Jul 26, 2023 07:25AM
Jul 26, 2023 07:25AM
Apr 26, 2023 07:25AM
Apr 26, 2023 07:25AM
Apr 4, 2023 07:25AM
Mar 16, 2023 07:25AM Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Mar 8, 2023 07:25AM
Feb 16, 2023 04:46PM
Feb 16, 2023 04:44PM
Jan 30, 2023 07:25AM
Jan 25, 2023 07:25AM
Jan 9, 2023 10:26AM
Jan 9, 2023 10:25AM Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
Nov 7, 2022 10:25AM
Oct 28, 2022 07:25AM
Oct 26, 2022 07:25AM
Oct 13, 2022 10:25AM
Sep 26, 2022 07:25AM
Sep 20, 2022 07:25AM
Aug 25, 2022 07:25AM Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe
Jul 22, 2022 07:25AM
Jul 6, 2022 11:00AM
Jun 23, 2022 11:00AM
Jun 2, 2022 08:00AM
Apr 27, 2022 07:41AM
Apr 27, 2022 07:40AM
Apr 6, 2022 09:34PM Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting
Jan 28, 2022 07:08AM
Jan 28, 2022 07:08AM
Jan 27, 2022 07:45AM
Dec 14, 2021 07:25AM
Dec 14, 2021 07:25AM
Nov 9, 2021 07:30AM
Nov 5, 2021 02:57AM Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases
Nov 4, 2021 07:30AM

329,911 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All